{'fraction_non_alphanumeric': 0.02671118530884808, 'fraction_numerical': 0.018363939899833055, 'mean_word_length': 4.769230769230769, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Desmopressin: the treatment of primary nocturnal enuresis].

OBJECTIVES
The efficacy of desmopressin, a drug that reduces nocturnal urine volume with no side effects, was evaluated in a group of 21 patients.


METHODS
20 boys and 1 girl with primary nocturnal enuresis were treated with intranasal desmopressin (DDAVP) for a period of 12 weeks.


RESULTS
An improvement in 80.95% was achieved. Following treatment enuresis recurred, but to a lesser degree than before therapy.


CONCLUSIONS
DDAVP is useful in the treatment of primary nocturnal enuresis whose etiology is not organic or functional.